Physician profile
Robert Micklas
NPI 1679722714
$4,613.04
in general payments reported to CMS, 2019-2025
36 companies · $515 in 2025
The $515 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,788 · 2022: $1,035 · 2023: $551 · 2024: $723 · 2025: $515.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,789.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,789.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,327.65 | 2021-2025 | |
| Biohaven Pharmaceuticals, INC. | $651.78 | 2021 | |
| Collegium Pharmaceutical, INC. | $322.17 | 2021-2024 | Xtampza |
| Biohaven Pharmaceutical Holding Company LTD. | $239.58 | 2022 | |
| Scilex Pharmaceuticals INC. | $229.84 | 2022-2023 | Ztlido |
| Amneal Pharmaceuticals LLC | $224.30 | 2021-2022 | |
| Upsher-Smith Laboratories LLC | $161.47 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $144.43 | 2021-2024 | Relistor |
| Neurelis, INC. | $141.92 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $141.03 | 2024-2025 | Caplyta |
| Idorsia Pharmaceuticals US INC | $140.87 | 2023-2024 | Quviviq |
| Takeda Pharmaceuticals U.S.A., INC. | $89.16 | 2021-2022 | |
| Lundbeck LLC | $81.92 | 2021-2025 | Vyepti |
| Horizon Therapeutics Plc | $75.70 | 2021-2022 | |
| Avanir Pharmaceuticals, INC. | $54.33 | 2021 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $52.66 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $50.56 | 2023-2024 | Rexulti |
| Axsome Therapeutics, INC. | $49.33 | 2024-2025 | Sunosi, Symbravo |
| Insightec,INC | $33.12 | 2025 | Exablate |
| Inspire Medical Systems, INC. | $32.53 | 2025 | Inspire |
| Novartis Pharmaceuticals Corporation | $32.47 | 2021 | |
| Immedica Pharma US, INC. | $30.36 | 2023 | |
| Biodelivery Sciences International, INC. | $29.96 | 2021 | |
| Tanabe Pharma America, INC. | $29.67 | 2025 | Radicava |
| Jazz Pharmaceuticals INC. | $28.63 | 2021-2022 | |
| Ucb, INC. | $27.24 | 2021 | |
| Neurocrine Biosciences, INC. | $24.50 | 2025 | |
| Acadia Pharmaceuticals INC | $23.87 | 2024 | Nuplazid |
| Valinor Pharma, LLC | $20.71 | 2024 | Movantik |
| Supernus Pharmaceuticals, INC. | $20.21 | 2021 | |
| Merck Sharp & Dohme LLC | $19.67 | 2023 | Belsomra |
| Pfizer INC. | $19.10 | 2024 | |
| Impel Pharmaceuticals INC. | $18.00 | 2022 | |
| Owp Pharmaceuticals, INC. | $17.41 | 2021 | |
| Lilly USA, LLC | $13.57 | 2021 | |
| Hikma Pharmaceuticals USA | $13.32 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Micklas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.